Drug Profile
Etanercept biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Alternative Names: Recombinant human TNF receptor p75-Fc fusion proteinLatest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 05 Sep 2017 No recent reports on development identified - Preregistration for Rheumatoid arthritis in China (Parenteral) (Shanghai Fudan Bio-Pharmaceutical website, September 2017)
- 12 May 2015 Preregistration for Rheumatoid arthritis in China (Parenteral) before May 2015